PT-141: A Central Arousal Signal, One Approved Indication

The short version

PT-141 is the name most people know, but its pharmaceutical identity is bremelanotide. It is a synthetic cyclic peptide — seven amino acids arranged in a ring — that activates a brain receptor called MC4R, which sits inside the hypothalamus and limbic system, two regions central to how the brain processes sexual desire. Unlike drugs that act on blood flow, it works on the neural side of arousal: the wanting, not just the physical response.

In 2019, the FDA approved bremelanotide for a single specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[5]. Two large Phase 3 trials across 1,267 women demonstrated statistically significant improvements in sexual desire and reductions in desire-related distress ^[3]. It is not approved for men, for postmenopausal women, or for enhancing sexual performance in people without HSDD — all of those uses are off-label. A real and common side effect is nausea. This page summarizes what was studied; it is not advice and lists no dose for any individual.

What it is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide lactam — a seven-amino-acid peptide with a chemical bridge (a lactam bond between the Asp and Lys side chains) that locks it into a ring shape. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, which is a truncated, cyclized, and chemically modified derivative of the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH).

The cyclization is important: it gives the peptide resistance to enzyme breakdown that the natural linear hormone lacks, and the C-terminal carboxylic acid group (rather than an amide) is one of two chemical differences between PT-141 and its structural relative Melanotan 2. PT-141 was developed specifically because it had the central arousal activity but greatly reduced pigmentation compared to that earlier analog ^[7][11]. The compound is a metabolite or structural relative of Melanotan II, but the two are distinct molecules with distinct regulatory histories and safety profiles — this distinction matters and this desk maintains it throughout.

How it works

PT-141 works primarily through MC4R (melanocortin 4 receptor), with additional activity at MC3R, concentrated in the hypothalamus and limbic brain regions — the neural territory of sexual motivation, not blood vessels ^[7].

In a 2022 neuroimaging study of 31 premenopausal women with HSDD, a single dose of the MC4R agonist significantly increased sexual desire for up to 24 hours and produced measurable changes in how the brain processed erotic stimuli: enhanced connectivity between the amygdala and insula, and increased activity in the cerebellum and supplementary motor area ^[2]. This is mechanistic evidence that the compound is genuinely engaging the central sexual-brain circuitry, not just producing peripheral blood-flow changes.

In female rats, PT-141 selectively increased appetitive, solicitational sexual behaviors — the seeking and motivation behaviors — without affecting lordosis (the reflexive response) or general movement, a distinction that established the central melanocortin system's role in the desire component of female sexual behavior ^[6]. Hypothalamic neuronal activation consistent with a central mechanism was also observed in rats and nonhuman primates, alongside dose-dependent erectile activity in men with erectile dysfunction ^[7].

Critically, this mechanism is distinct from PDE-5 inhibitors, which relax vascular smooth muscle. PT-141 produces its effects upstream, in the brain circuitry that generates the desire to have sex, not in the blood vessels that enable erection or lubrication.

What the research shows

The Phase 3 RECONNECT trials. The pivotal evidence comes from two identical, randomized, double-blind, placebo-controlled trials (combined n=1,267 premenopausal women with HSDD) ^[3]. Over 24 weeks, bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant improvement in sexual desire (integrated FSFI-desire score +0.35, P<.001) and a statistically significant reduction in desire-related distress (FSDS-DAO item 13, -0.33, P<.001) compared with placebo. Both co-primary endpoints were met in both trials. The most common adverse events were nausea, flushing, and headache ^[3].

Long-term extension. The 52-week open-label extension of RECONNECT enrolled 684 women ^[4]. Sexual-desire improvements were sustained throughout without new safety signals. The most common drug-related treatment-emergent adverse events over the long term were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[4].

Neuroimaging. In a randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and produced changes in task-based brain processing in response to erotic stimuli — including enhanced amygdala-insula functional connectivity ^[2]. This is the most direct evidence of central sexual-brain engagement in humans.

Animal mechanistic studies. In female rats, the compound selectively increased appetitive sexual behaviors without affecting consummatory responses ^[6]. In male rats and nonhuman primates, it activated hypothalamic neurons and produced dose-dependent erectile activity, with early data in men with erectile dysfunction ^[7]. A 2025 female Syrian hamster study found that MC3R/MC4R mRNA was concentrated in ventral tegmental area dopamine neurons, and that bremelanotide at study doses did not enhance sexual reward in a conditioned-place-preference model, suggesting it does not act primarily through the VTA-nucleus-accumbens reward circuit ^[1] — a nuanced finding that underscores the complexity of its central mechanism.

What the prescribing label confirms. The FDA-approved label specifies the HSDD indication, the pharmacokinetic profile (terminal half-life ~2.7 h, volume of distribution 25.0 L), and the key safety warning regarding transient blood-pressure increase ^[5]. It also confirms the approved frequency limits, which exist partly to limit cumulative pigmentation effects from off-target MC1R activity ^[5].

Reported effects, cautions & safety

The following reported effects come from people in research-use communities, drug-review platforms, and qualitative accounts. They are anecdotal, not clinical evidence, presented because they are part of the real-world record — not to recommend use.

Reported benefits (anecdotal):

• Stronger sexual desire and 'wanting': The most commonly reported effect is a felt increase in sexual desire that starts in the brain — people describe wanting sex again and feeling mentally switched on in a way that blood-flow drugs do not produce. Reports stress this is about motivation and interest.
• Greater physical arousal and sensitivity: People commonly report feeling more physically responsive and more sensitive to touch. Some describe arousal building on its own without direct stimulation, and a few describe waking up aroused hours after a dose.
• Easier or more intense orgasm: Some users report orgasms that come more easily or feel more intense. This is reported as a secondary effect, variable between individuals.
• Spontaneous erections in men (off-label): In the off-label male research-use community, people frequently report spontaneous erections and a stronger sense of sexual interest, described as distinct from blood-flow drugs because the urge comes first. This use is not approved.
• Longer, delayed window of effect: People note effects can take a half-hour to a few hours to appear and can last well into the following day — described by many as a feature, by others as inconvenient.
• Stronger sense of emotional connection: Some users report feeling more emotionally engaged during intimacy, though this is less common and not a measured outcome.

Reported adverse effects (anecdotal and confirmed in trials):

• Nausea: By far the most common complaint — reported by approximately 40% of users over long-term use ^[4]. Ranges from a brief queasy wave to severe nausea with vomiting. Usually worst with the first dose.
• Flushing and warmth: A warm, flushed face and neck appearing within the first hour, fading within a few hours ^[4].
• Headache: Common, usually mild and short-lived ^[4].
• Injection-site irritation: Redness, soreness, or small lumps at the injection site.
• Fatigue or drowsiness: Reported by some users as clearing the same day.
• Tingling, pins-and-needles, or skin sensitivity: Clustered with flushing and nausea, passing within hours.
• No effect at all: A real and recurring report — some people experience only side effects with no improvement in desire or arousal. Individual response varies substantially.

Clinical safety cautions:

• Approved only for premenopausal women with HSDD: Any other use — in men, postmenopausal women, or for performance enhancement without an HSDD diagnosis — is off-label and outside the studied population ^[5].
• Transient blood-pressure increase: The approved label explicitly warns against use in people with uncontrolled hypertension or known cardiovascular disease ^[5].
• Skin and mucous-membrane darkening with frequent dosing: Because the compound also activates pigment-making MC1R receptors, repeated frequent dosing can cause darkening of the face, gums, and breasts and changes in existing moles. This is why the label limits dosing frequency ^[5].
• Possible liver enzyme changes: Mild rises in liver-related markers and rare clinically apparent liver injury have been noted in monitoring literature; people with existing liver concerns should be aware of this signal.
• Unregulated 'research chemical' supply: Material sold outside the pharmacy system has no quality control for identity, purity, or concentration. Forensic testing of black-market melanocortin peptides confirms variable and unregulated product circulates ^[7].
• Pregnancy and breastfeeding: No controlled human data establish safety for a developing baby or nursing infant. Use in these groups is unsupported.

Where it fits in the melanocortin research picture

PT-141 holds a specific and unusual position in this desk's two-compound frame: it is the only compound here with an FDA approval, but that approval is narrow — one indication, one population, one sex ^[5]. Its central mechanism through MC4R is well characterized, with human neuroimaging data directly demonstrating brain-level engagement ^[2], and its Phase 3 efficacy is from the largest trials of any compound on this desk ^[3]. Its selectivity for MC4R over MC1R also means its pigmentation side-effect burden is lower than Melanotan 2, though not zero at high-frequency dosing.

What it does not have is an approval — or strong controlled-trial evidence — for use in men, for postmenopausal women, or for the off-label population that encounters it most often in research-use contexts. Compare the two peptides to see how selectivity, evidence depth, and regulatory status line up side by side.